Fresenius Medical Care announced the acquisition of further dialysis centers and renal hospitals throughout China.
Fresenius acquired a 70% share of the dialysis and related chronic disease services company, Guangzhou KangNiDaiSi Medical Investment Co. Ltd. KangNiDaiSi has three independent hemodialysis centers under construction in cities in the Guangdong province, and a fourth center in Guangzhou awaits government approval.
“These acquisitions mark an important strategic step in our business development in China. As the second largest product market, China is already today an important business growth driver for Fresenius Medical Care,” said Rice Powell, CEO of Fresenius Medical Care. “We have been continuously investing in enhancing our product range within the local market. We have also started to enter the provider business to introduce advanced dialysis services and operations management in China.”
It also acquired 55% shares in both the Henan Aishen Hospital Management Co. Ltd. and Aishen Beijing Hospital Management Co. Ltd. The newly acquired companies have 13 dialysis centers and a grade I renal hospital under construction.
In addition, the company took a 60% share of Daqing Kangda Dialysis Center Co. Ltd. in the Heilongjiang province.
“As a leading provider of dialysis products and services in China, we are eager to work with other companies that are dedicated to elevating the treatment of kidney disease in this huge country. In particular, we focus on increasing access to treatment in rural areas, where there have traditionally been fewer options for patients,” said Harry de Wit, CEO of Fresenius Medical Care Asia-Pacific. “We strive to introduce our world-leading chronic disease management system and high-quality dialysis treatment services throughout the country. And we will continue to search for opportunities to partner with institutions from the public and private sectors and invest in new dialysis centers and renal hospitals.”